pyrazines has been researched along with Bladder Cancer in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Grivas, P; Khaki, AR; Pal, SK | 1 |
| Cui, Y; Dreicer, R; Emamekhoo, H; Frankel, PH; Hoimes, C; Kim, WY; Lara, PN; Lyou, Y; Michaelson, D; Milowsky, M; Mortazavi, A; Newman, E; Pal, SK; Parikh, M; Parikh, R; Srinivas, S; Teply, B; Vaishampayan, U; Weng, P; Zhang, T | 1 |
| Choi, W; Dinney, C; Guo, C; McConkey, DJ; Qi, W; Siefker-Radtke, A; White, MC | 1 |
| Cheung, YK | 1 |
| Fischer, U; Hoffmann, MJ; Jung, M; Niegisch, G; Rosik, L; Schulz, WA | 1 |
| Itoh, K; Liu, T; Maruyama, A; Mimura, J; Ohyama, C; Okada, T; Sato, H; Ye, P | 1 |
| Chao, H; Fu, B; Peng, L; Wang, G; Wang, Y; Xi, H; Zeng, T; Zhu, Z | 1 |
| Lei, T; Wang, S; Zhang, M | 1 |
| Masmiquel Comas, L; Nicolau Ramis, J | 1 |
| Dai, G; Wang, X | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Akaza, H; Hattori, K; Iida, K; Itoh, K; Kawai, K; Kumagai, Y; Oyasu, R; Shimazui, T; Yamamoto, M | 1 |
| Benedict, W; Dinney, CP; Grossman, HB; Lashinger, L; McConkey, DJ; Millikan, R; Papageorgiou, A | 1 |
| Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F | 1 |
| Dinney, CP; Lashinger, LM; McConkey, DJ; Shrader, M; Williams, SA; Zhu, K | 1 |
| Benedict, WF; Dinney, C; Kamat, A; McConkey, DJ; Papageorgiou, A | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 1 |
1 review(s) available for pyrazines and Bladder Cancer
| Article | Year |
|---|---|
[Development of bladder cancer chemoprevention].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Papillary; Humans; Neoplasm Recurrence, Local; Piroxicam; Pyrazines; Retinoids; Thiones; Thiophenes; Urinary Bladder Neoplasms | 2003 |
1 trial(s) available for pyrazines and Bladder Cancer
| Article | Year |
|---|---|
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Isoxazoles; Male; Pyrazines; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
15 other study(ies) available for pyrazines and Bladder Cancer
| Article | Year |
|---|---|
Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Benzamides; Humans; Immunotherapy; Pyrazines; Urinary Bladder Neoplasms | 2020 |
Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Methylation; DNA Primers; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HSP72 Heat-Shock Proteins; Humans; Immunoblotting; Microarray Analysis; Protein Isoforms; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms | 2013 |
Simple benchmark for complex dose finding studies.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Benchmarking; Biometry; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Lymphoma; Models, Statistical; Pyrazines; Stroke; Urinary Bladder Neoplasms | 2014 |
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Topics: Acetylation; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Indoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Middle Aged; Protein Processing, Post-Translational; Pyrazines; Urinary Bladder Neoplasms; Urothelium | 2014 |
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Topics: Activating Transcription Factor 4; Amino Acid Transport System y+; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glutathione; Glycine; HEK293 Cells; HeLa Cells; Humans; Leupeptins; NF-E2-Related Factor 2; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering; Sulfasalazine; Urinary Bladder Neoplasms | 2014 |
IRE1α-TRAF2-ASK1 complex-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to CXC195-induced apoptosis in human bladder carcinoma T24 cells.
Topics: Apoptosis; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoribonucleases; Gene Knockdown Techniques; Humans; MAP Kinase Kinase Kinase 5; Mitochondria; Oxidative Stress; Piperazines; Protein Serine-Threonine Kinases; Pyrazines; TNF Receptor-Associated Factor 2; Urinary Bladder Neoplasms | 2015 |
The Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder Cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Catechin; Cell Cycle; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Neoplasm Proteins; Pyrazines; Urinary Bladder Neoplasms | 2016 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; DNA-Binding Proteins; Enzyme Induction; Female; Gene Expression; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Inactivation, Metabolic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Microsomes, Liver; NF-E2-Related Factor 2; Pyrazines; Thiones; Thiophenes; Trans-Activators; Urinary Bladder; Urinary Bladder Neoplasms | 2004 |
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Caspase 8; Caspase Inhibitors; Caspases; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Humans; Interferon Type I; Membrane Glycoproteins; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2004 |
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2005 |
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Fibroblast Growth Factor 2; Humans; Interferon-alpha; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |